ClinicalTrials.gg
RecruitingNCT07355478Updated Oct 8, 2026

Asia Myelodysplastic Syndrome (MDS) Registry

An observational study in Myelodysplastic Syndromes (MDS), sponsored by Bristol-Myers Squibb. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Bristol-Myers Squibb · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 8, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb — 4 open to participants now, 9 under way, 5 of them phase 3. Myelodysplastic Syndromes · Bristol-Myers Squibb.

Planned enrollment
6th of 28
500 · median 200
Started
2026
with 2 others
Observational
28 of 75
3 open now
Registered
73rd of 75
by date

Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, this one is the 6th largest by planned enrollment of the 28 observational ones that give a count, is one of 3 that started in 2026, is one of 28 observational ones, and was the 73rd registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

4 of the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.

03

Conditions studied

  • Myelodysplastic Syndromes (MDS)

Keywords

  • Myelodysplastic syndromes (MDS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The registry will include adults who were/are newly diagnosed with myelodysplastic syndromes (MDS) in Asia (Singapore, South Korea and Taiwan).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Retrospective enrolment of Myelodysplastic Syndrome (MDS) participants:

  • Aged at least 18 years at initial diagnosis of MDS
  • Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 January 2019 and 31 December 2022; and
  • Diagnosed with MDS within 100 days from the date of diagnostic bone marrow (BM) aspirate

Inclusion criteria for the prospective enrolment of MDS participants:

  • Aged at least 18 years at initial diagnosis of MDS; and
  • Diagnosed with MDS according to World Health Organization (WHO) 2008, WHO 2016, or WHO 2022 criteria between 1 October 2025 and 30 September 2026; and
  • Diagnosed with MDS within 100 days from the date of diagnostic BM aspirate

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
500 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Group 1

    Participants diagnosed with myelodysplastic syndromes (MDS)

    Drug: Prescribed treatments for myelodysplastic syndromes (MDS)

Interventions

  • DrugPrescribed treatments for myelodysplastic syndromes (MDS)

    According to the product label

06

What researchers measure

Primary outcomes

  1. Participant age

    Time frame: Baseline

  2. Participant sex

    Time frame: Baseline

  3. Participant race

    Time frame: Baseline

  4. Participant weight

    Time frame: Baseline

  5. Participant height

    Time frame: Baseline

  6. Participant body mass index (BMI)

    Time frame: Baseline

  7. Participant smoking status

    Time frame: Baseline

  8. Participant drinking status

    Time frame: Baseline

  9. Family history of MDS or other hematopoietic cancers

    Time frame: Baseline

  10. Participant myelodysplastic syndromes diagnosis information

    Time frame: Baseline

  11. Participant Eastern Cooperative Oncology Group (ECOG) Performance status at diagnosis

    Time frame: Baseline

  12. Participant comorbidities at diagnosis

    Time frame: Baseline

  13. Participant Charlson comorbidity index (CCI) score at diagnosis

    Time frame: Baseline

  14. Prior clinical diagnosis of other cancers

    Time frame: Baseline

  15. Prior clinical diagnosis of hematological diseases

    Time frame: Baseline

  16. Anemia status at diagnosis

    Time frame: Bseline

  17. Thrombocytopenia status at diagnosis

    Time frame: Baseline

  18. Neutropenia status at diagnosis

    Time frame: Baseline

  19. Iron overload status at diagnosis

    Time frame: Baseline

  20. Red blood cell (RBC) transfusion dependence status at diagnosis

    Time frame: Baseline

  21. International Prognostic Scoring System (IPSS) score at diagnosis

    Time frame: Baseline

  22. Revised International Prognostic Scoring System (IPSS-R) score at diagnosis

    Time frame: Baseline

  23. Molecular International Prognostic Scoring System (IPSS-M) score at diagnosis

    Time frame: Baseline

  24. Bone marrow aspirate results

    Time frame: Baseline and up to 2-years

  25. Presence of dysplasia

    Time frame: Baseline and up to 2-years

  26. Cytogenetic test results

    Time frame: Baseline and up to 2-years

  27. Mutation test results at diagnosis

    Time frame: Baseline

  28. Complete blood count test results at diagnosis

    Time frame: Baseline

  29. Mean corpuscular volume (MCV)

    Time frame: Baseline and up to 2-years

  30. C-reactive protein (CRP)

    Time frame: Baseline and up to 2-years

  31. Serum ferritin (SF) level

    Time frame: Baseline and up to 2-years

  32. Serum erythropoietin levels

    Time frame: Baseline and up to 2-years

  33. Lactate dehydrogenase (LDH)

    Time frame: Baseline and up to 2-years

Secondary outcomes

  1. Initial treatment received following diagnosis

    Time frame: Baseline

  2. Prior treatments and concomitant medications received

    Time frame: Baseline

  3. Subsequent treatments received

    Time frame: Up to 2-years

  4. Time from diagnosis to treatment initiation

    Time frame: Baseline

  5. Treatment duration

    Time frame: Up to 2-years

  6. Real-world overall survival (rwOS)

    Time frame: Baseline and up to 2-years

  7. Time to disease-risk progression (per IPSS-R)

    Time frame: Baseline and up to 2-years

  8. Time to acute myeloid leukemia (AML) progression

    Time frame: Baseline and up to 2-years

  9. Time to iron overload

    Time frame: Baseline and up to 2-years

  10. Overall response rate (ORR)

    Time frame: Baseline and up to 2-years

  11. Duration of response (DOR)

    Time frame: Baseline and up to 2-years

  12. Real-world relapse-free survival (rwRFS)

    Time frame: Baseline and up to 2-years

07

Study locations

1 of 3 sites recruiting
  • Singapore General Hospital
    Singapore, 169608, Singapore
    Recruiting
    • Nurul Aidah, Site 0003 · Contact
  • Local Institution - 002
    Seoul, Seoul Teugbyeolsi 03080, South Korea
    Not yet recruiting
    • Site 002 · Contact
  • Local Institution - 0001
    Taipei, 100229, Taiwan
    Not yet recruiting
    • Site 0001 · Contact
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Oct 2026, 2 months after the start.

Of 102 observational studies under Myelodysplastic Syndromes, half reached primary completion within 84 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 154. This study's planned 2 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Aug 2026, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2025
First posted
Jan 21, 2026
StartActual
Aug 11, 2026was Mar 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Sep 30, 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
1 site added, 1 site removed. 2 sites changed recruiting status (2 now not yet recruiting)
Show 2 sites
  • Local Institution - 002 · Seoul, South Koreano status→Not yet recruiting
  • Local Institution - 0001 · Taipei, Taiwanno status→Not yet recruiting
Show site
  • Singapore General Hospital · Singapore, Singapore
Show 1 removed
  • Local Institution - 0003 · Singapore, Singapore
Oct 8, 2026
Start date
Mar 26, 2026→Aug 11, 2026 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Recruiting
    1 site added, 1 site removed. 2 sites changed recruiting status (2 now not yet recruiting)
    Show 2 sites
    • Local Institution - 002 · Seoul, South Koreano status→Not yet recruiting
    • Local Institution - 0001 · Taipei, Taiwanno status→Not yet recruiting
    Show site
    • Singapore General Hospital · Singapore, Singapore
    Show 1 removed
    • Local Institution - 0003 · Singapore, Singapore
    Start date Mar 26, 2026→Aug 11, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07355478
Responsible party
Sponsor
First posted
Jan 21, 2026
Start date
Aug 11, 2026
Primary completion
Oct 31, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 8, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol Myers Squibb
study director · Bristol-Myers Squibb
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion